Skip to main content

FSHD

2
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Avidity Biosciences
Avidity BiosciencesCA - San Diego
3 programs
1
1
AOC 1020Phase 21 trial
AOC 1020Phase 1/21 trial
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)N/A
Active Trials
NCT05747924Completed90Est. Mar 2026
NCT06547216Enrolling By Invitation84Est. Apr 2028
Dyne Therapeutics
1 program
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)N/A
Genentech
GenentechCA - Oceanside
1 program
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)N/A1 trial
Active Trials
NCT04635891Recruiting450Est. Jan 2028
AMRA Medical
AMRA MedicalSweden - Linköping
1 program
Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)N/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Avidity BiosciencesAOC 1020
Avidity BiosciencesAOC 1020
GenentechMotor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

Clinical Trials (3)

Total enrollment: 624 patients across 3 trials

Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD)

Start: Jul 2024Est. completion: Apr 202884 patients
Phase 2Enrolling By Invitation

Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Start: Apr 2023Est. completion: Mar 202690 patients
Phase 1/2Completed
NCT04635891GenentechMotor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

Motor Outcomes to Validate Evaluations in FSHD (MOVE FSHD)

Start: Dec 2020Est. completion: Jan 2028450 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 624 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.